What Is Mitochondrial Health — And Why It Matters

Mitochondria occupy a central position in modern longevity science — yet they remain one of the most misunderstood structures in biology. Often reduced to the phrase "powerhouses of the cell," mitochondria are in reality dynamic, signal-emitting organelles that regulate energy production, cellular stress responses, metabolic flexibility, and the pace of biological aging. Understanding mitochondrial health is not merely academic: the quality and efficiency of mitochondrial function are increasingly recognised as a unifying axis linking fatigue, metabolic disease, immune decline, neurodegeneration, and longevity.

This article introduces the foundational biology of mitochondria — how they produce energy, how they renew themselves, what happens when they fail, and how key biomarkers and emerging compounds such as NAD⁺ and Urolithin A connect to this system.

1. Mitochondrial Structure and the Energy Production System

Mitochondria are double-membrane organelles present in virtually every nucleated human cell, numbering from a few hundred in resting fibroblasts to several thousand in cardiomyocytes and skeletal muscle fibres — tissues with exceptional energy demands. Their architecture is precisely organised: an outer membrane permeable to small molecules, and a highly selective inner membrane that folds into deep invaginations called cristae. These cristae are not merely structural features — they concentrate the molecular machinery of energy production and their geometry directly regulates metabolic output.

Embedded within the inner membrane are five protein complexes that constitute the electron transport chain (ETC) and ATP synthase:

• Complex I (NADH:ubiquinone oxidoreductase) — oxidises NADH generated by the TCA cycle, transferring electrons to ubiquinone (CoQ10) and pumping four protons across the inner membrane.
• Complex II (succinate dehydrogenase) — links the TCA cycle to the ETC by oxidising succinate; does not directly pump protons.
• Complex III (cytochrome bc₁) — transfers electrons from CoQ10 to cytochrome c and pumps four protons, contributing significantly to the proton gradient.
• Complex IV (cytochrome c oxidase) — the terminal enzyme, reducing molecular oxygen to water and pumping two protons. The final destination of the electron flow.
• Complex V (ATP synthase) — harnesses the electrochemical proton gradient (protonmotive force, Δp) established by Complexes I, III, and IV to phosphorylate ADP into ATP, yielding approximately 30–32 ATP molecules per molecule of glucose under optimal conditions.

Research has established that these complexes do not operate in isolation. They assemble into higher-order structures called respiratory supercomplexes — or respirasomes — most commonly in the configuration I+III₂+IV. Stabilised by the phospholipid cardiolipin, these assemblies optimise electron channelling, reduce the production of damaging reactive oxygen species (ROS), and improve the overall efficiency of oxidative phosphorylation (OXPHOS).

Mitochondria also carry their own genome: a compact circular DNA molecule of approximately 16,569 base pairs (mtDNA), encoding 13 essential OXPHOS subunits, 22 transfer RNAs, and 2 ribosomal RNAs. With a coding density approaching 93% and a mutation rate substantially higher than nuclear DNA, mtDNA integrity is a critical determinant of long-term mitochondrial function. Critically, each cell contains hundreds to thousands of mtDNA copies — and the balance between normal and mutant copies, known as heteroplasmy, determines whether dysfunction becomes clinically apparent.

2. Mitochondrial Biogenesis: The PGC-1α Master Switch

Cells respond to increased energy demand — during exercise, caloric restriction, cold exposure, or metabolic stress — by generating new mitochondria, a process called mitochondrial biogenesis. This process is coordinated by PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), a transcriptional coactivator widely regarded as the master regulator of mitochondrial mass and function.

PGC-1α does not bind DNA directly. Instead, it coactivates a cascade of downstream transcription factors: NRF1 and NRF2 (nuclear respiratory factors), which drive expression of TFAM (mitochondrial transcription factor A) — the protein responsible for mtDNA replication, transcription, and packaging. PGC-1α also coactivates ERRα, PPARα, and PPARδ to promote fatty acid oxidation, antioxidant gene expression, and mitochondrial protein import.

Multiple upstream signalling pathways converge on PGC-1α, forming what is now understood as the core nutrient-sensing and energy-sensing axis:

• AMPK (AMP-activated protein kinase) — activated when AMP/ATP ratios rise during exercise, fasting, or caloric restriction. AMPK directly phosphorylates PGC-1α at Thr177 and Ser538, initiating biogenesis. AMPK also phosphorylates and activates SIRT1.
• SIRT1 — a NAD⁺-dependent deacetylase that removes inhibitory acetyl groups from PGC-1α, further increasing its transcriptional activity. SIRT1 activity is directly dependent on cellular NAD⁺ availability.
• p38 MAPK and CaMKIV — activated during muscle contraction and calcium signalling, converging on PGC-1α to coordinate exercise-induced biogenesis.

The result is a feedforward circuit: physical activity or caloric restriction raises the AMP/ATP ratio and cellular NAD⁺, activating AMPK and SIRT1, which together activate PGC-1α, which drives the synthesis of new mitochondria and their internal machinery. This is the molecular basis for the well-established benefits of aerobic exercise on metabolic health — and the reason why NAD⁺ levels, which decline substantially with age, have attracted significant scientific and commercial interest.

3. Mitochondrial Dynamics: A Continuous Cycle of Fusion, Fission, and Renewal

Mitochondria are not static organelles. They exist in a perpetual state of structural remodelling, continuously merging (fusion) and dividing (fission) in response to cellular conditions. This dynamic behaviour is not incidental — it is an essential quality control mechanism.

Fusion is mediated by the GTPases MFN1 and MFN2 on the outer membrane, and OPA1 on the inner membrane. Fusion enables content mixing between mitochondria, allows complementation of damaged mtDNA copies from healthy ones, and promotes more efficient OXPHOS under nutrient sufficiency. Conditions that impair fusion — including OPA1 mutations causing Dominant Optic Atrophy — result in fragmented mitochondrial networks and progressive tissue dysfunction.

Fission is executed by DRP1, a cytosolic GTPase recruited to the outer membrane by adaptor proteins MFF, FIS1, MiD49, and MiD51. Endoplasmic reticulum tubules pre-constrict mitochondria before DRP1 oligomerises into contractile rings to complete the division. Fission enables asymmetric segregation of damaged components, facilitates mitochondrial transport to distal cellular sites, and is a prerequisite for the targeted elimination of dysfunctional mitochondria.

When a mitochondrion sustains irreparable damage — most commonly signalled by a collapse of inner membrane potential (ΔΨm) — it is removed via mitophagy: selective autophagy targeting mitochondria. The canonical pathway is governed by the kinase PINK1 and the E3 ubiquitin ligase Parkin:

• On healthy mitochondria, PINK1 is continuously imported into the inner membrane and cleaved by PARL, keeping its levels low.
• When ΔΨm collapses, import is blocked, PINK1 accumulates on the outer membrane, dimerises, and autophosphorylates.
• Activated PINK1 phosphorylates both ubiquitin (at Ser65) and Parkin (at Ser65 of its UBL domain), recruiting Parkin to the mitochondrial surface.
• Parkin ubiquitinates outer membrane proteins including MFN1/2 (blocking fusion) and VDAC1, generating ubiquitin chains recognised by autophagy receptors OPTN, NDP52, and p62.
• These receptors bridge ubiquitinated mitochondria to the LC3-decorated autophagosome membrane, leading to lysosomal degradation.

Crucially, the PINK1/Parkin system also couples destruction with renewal: by degrading PARIS (ZNF746), an inhibitor of PGC-1α, active Parkin simultaneously derepresses the biogenesis programme — ensuring that eliminated mitochondria are replaced. The clinical significance of this pathway is underscored by the finding that loss-of-function mutations in PINK1 (PARK6) and Parkin (PARK2) represent the most common genetic causes of early-onset Parkinson's disease.

4. Mitochondrial Dysfunction and the Biology of Aging

Mitochondrial dysfunction is recognised as one of the fundamental hallmarks of aging, interacting with and amplifying several others including oxidative stress, genomic instability, cellular senescence, chronic inflammation, and stem cell exhaustion.

4.1 Reactive Oxygen Species: Signal and Damage

The ETC is the primary source of cellular reactive oxygen species (ROS). Under normal conditions, approximately 0.1–2% of electron flow results in incomplete reduction of molecular oxygen, generating superoxide (O₂•⁻), primarily at Complex I (via reverse electron transport) and Complex III (at the Qo site). Superoxide is rapidly converted to hydrogen peroxide (H₂O₂) by SOD2 (MnSOD) within the mitochondrial matrix, then further neutralised by glutathione peroxidase, catalase, and peroxiredoxins.

At physiological concentrations, mitochondrial H₂O₂ functions as a signalling molecule, activating adaptive cytoprotective pathways — a phenomenon termed mitohormesis. Research has shown that mild ROS stress induced by caloric restriction or exercise activates pathways that extend lifespan, and that supplementing with high-dose antioxidants can paradoxically abolish these benefits. This finding has substantially reframed the original "free radical theory of aging" toward a more nuanced signalling model.

When antioxidant defences are overwhelmed — through excessive ROS production, impaired clearance, or both — oxidative damage to mtDNA, proteins, and membrane lipids accumulates. Critically, however, contemporary genomic evidence has shifted understanding of mtDNA mutations in aging: most somatic mutations are now understood to arise primarily as replication errors by DNA polymerase γ, not as direct consequences of oxidative damage. The pattern of transition mutations that accumulates with age does not match the signature of oxidative guanine damage — a finding that complicates simple oxidative stress narratives.

4.2 The NAD⁺ Decline — A Convergence Point

Perhaps the most therapeutically relevant mechanism connecting mitochondrial aging to measurable biology is the age-related decline in cellular NAD⁺. NAD⁺ serves dual roles: as an essential redox cofactor shuttling electrons within the ETC and TCA cycle (as NADH), and as an obligate co-substrate for the sirtuin deacetylases, PARP DNA repair enzymes, and CD38 hydrolase. With age, cellular NAD⁺ concentrations fall substantially — driven primarily by increased activity of CD38 (the dominant cellular NADase) and PARP enzymes, alongside decreased expression of NAMPT (the rate-limiting enzyme in the NAD⁺ salvage pathway).

The functional consequence is a self-amplifying degenerative cycle: declining NAD⁺ reduces SIRT1 activity → hyperacetylated, inactive PGC-1α → impaired biogenesis; reduced SIRT3 activity within mitochondria → hyperacetylated SOD2 and ETC subunits → increased ROS → greater DNA damage → increased PARP consumption → further NAD⁺ depletion. Landmark research by Gomes et al. (2013) demonstrated that declining NAD⁺ in aged mice leads to a "pseudohypoxic" state in which HIF-1α accumulates under normoxia, disrupting nuclear-mitochondrial communication and selectively impairing the expression of mtDNA-encoded OXPHOS subunits. The same study showed that NAD⁺ repletion with NMN restored youthful mitochondrial function in a SIRT1-dependent manner — establishing reversibility as a key principle.

Within the mitochondrial matrix, SIRT3 — whose expression is itself driven by PGC-1α — deacetylates and activates ETC Complexes I, II, and V, SOD2 (increasing its antioxidant capacity ~3-fold), IDH2 (recycling NADPH for glutathione), and LCAD (promoting fatty acid β-oxidation). The PGC-1α → SIRT3 → SOD2 axis represents a coherent feedforward loop linking biogenesis to antioxidant capacity.

4.3 Senescence-Associated Mitochondrial Dysfunction

Dysfunctional mitochondria play an active role in the acquisition and maintenance of cellular senescence. Senescent cells display a characteristic metabolic rewiring toward glycolysis, impaired OXPHOS, elevated ROS, and resistance to apoptosis. Mitochondria in senescent cells contribute to the senescence-associated secretory phenotype (SASP) — the pro-inflammatory cytokine milieu that drives tissue dysfunction — through mitochondrial ROS production and the release of mtDNA fragments that activate cGAS-STING innate immune sensing. This positions impaired mitophagy as a contributor not only to energy deficits but to the chronic low-grade inflammation increasingly associated with aging ("inflammaging").

5. Urolithin A and Mitophagy: A First-in-Class Intervention

Urolithin A (UA) is a gut microbiome-derived postbiotic metabolite produced when colonic bacteria — primarily Gordonibacter and certain Bifidobacterium species — metabolise dietary ellagitannins and ellagic acid found in pomegranates, walnuts, raspberries, and strawberries. Critically, only approximately 40% of adults produce UA at biologically meaningful plasma concentrations, a variability determined by gut microbiome composition — making direct supplementation the only reliable delivery strategy.

UA is the first compound identified to act as a direct, selective mitophagy inducer in mammals. Its mechanism operates through two complementary pathways:

• PINK1/Parkin-dependent mitophagy: UA upregulates the expression of both PINK1 and Parkin, lowering the activation threshold for mitophagy on damaged mitochondria. The resulting ubiquitin cascade drives selective autophagosomal engulfment and lysosomal clearance of dysfunctional mitochondria.
• BNIP3-dependent mitophagy: UA increases mitochondrial BNIP3 levels, providing an alternative receptor that directly recruits LC3 for autophagosome formation — extending mitophagy induction independently of membrane potential collapse.

Importantly, UA does not merely eliminate mitochondria — it simultaneously activates biogenesis via AMPK phosphorylation → PGC-1α → NRF1/NRF2 → TFAM, ensuring that cleared mitochondria are replaced by new, healthy ones. Mechanistic studies have further shown that PINK1-mediated mitophagy releases the mitochondrial phosphatase Pgam5 into the cytosol, which dephosphorylates β-catenin and activates Wnt signalling to drive compensatory biogenesis — coupling destruction and renewal at the molecular level.

The clinical evidence base for UA has grown substantially over the past six years:

• A Phase 1 first-in-human trial (Andreux et al., 2019, Nature Metabolism) confirmed the safety and bioavailability of supplemental UA at doses up to 1000 mg/day, with gene expression analysis in muscle biopsies demonstrating upregulation of mitochondrial quality-control and biogenesis genes — a molecular signature resembling the response to exercise training.
• A randomised controlled trial (Singh et al., 2022, Cell Reports Medicine) in middle-aged adults demonstrated approximately 12% improvement in leg muscle strength, a 10% increase in peak VO₂, and a 7% improvement in six-minute walk test performance following 4 months of 1000 mg/day UA supplementation, accompanied by reductions in plasma acylcarnitines, ceramides, and high-sensitivity CRP.
• A randomised clinical trial (Liu et al., 2022, JAMA Network Open) in older adults aged 65–90 showed improved muscle endurance and favourable shifts in circulating biomarkers of mitochondrial health following UA supplementation.
• A recent Nature Aging trial (Denk et al., 2025) demonstrated that UA supplementation in middle-aged adults expanded naive CD8+ T-cell populations and increased fatty acid oxidation capacity and PGC-1α expression in immune cells — connecting mitophagy induction to age-related immune decline.

Research has also explored UA's role in models of Duchenne muscular dystrophy, Alzheimer's disease, and anti-tumour immunity, suggesting a broad tissue applicability of mitophagy induction beyond skeletal muscle.

6. Biomarker Mapping: Measuring Mitochondrial Health

No single biomarker captures the full complexity of mitochondrial function. Current expert consensus advocates a panel approach combining functional, metabolic, and stress-response markers across multiple biological domains.

Primary Biomarkers

• NAD⁺ — Reflects the redox and sirtuin-signalling capacity of the mitochondrial system. Measured in whole blood or dried blood spots (DBS) by HPLC or LC-MS/MS. Levels decline significantly with age and are directly tied to the AMPK–SIRT1–PGC-1α biogenesis axis. Available through the Biostarks Longevity NAD⁺ panel.
• Lactate:Pyruvate ratio — A functional proxy for the cytosolic NADH/NAD⁺ redox state and OXPHOS integrity. A ratio above 20 suggests impaired respiratory chain function. Measured in plasma by enzymatic spectrophotometry; widely available through clinical laboratories.
• CoQ10 (Coenzyme Q10) — The essential electron carrier between Complexes I/II and III; also functions as a lipid-soluble antioxidant within the inner membrane. Measured in plasma by HPLC-UV or LC-MS/MS. Clinically actionable and directly relevant to supplementation decisions, particularly in individuals using statins, which reduce endogenous CoQ10 synthesis.
• GDF-15 — A mitokine released under conditions of mitochondrial stress; produced by the integrated stress response (ISR) upon OXPHOS impairment. Serum GDF-15 carries the highest diagnostic accuracy of any single mitochondrial biomarker in clinical studies (AUC 0.82–0.94 in mitochondrial disease cohorts), though it is also elevated by inflammation, cancer, and cardiovascular disease.
• FGF-21 — A hepatic stress hormone elevated 7–17-fold in mitochondrial myopathies; also produced by muscle in response to OXPHOS dysfunction. Highly sensitive and specific in the context of primary mitochondrial disease; emerging as a health monitoring marker in aging populations.
• Urinary organic acids — A broad-spectrum metabolic window into TCA cycle efficiency, fatty acid oxidation, and amino acid catabolism. Key analytes in the mitochondrial context include 3-methylglutaconic acid, ethylmalonate, succinate, fumarate, and 2-hydroxyglutarate. Measured by GC-MS or LC-MS/MS; available through specialty clinical laboratories.

Secondary and Contextual Biomarkers

• GSH/GSSG ratio — The glutathione redox couple; reflects the overall cytosolic antioxidant buffering capacity and SIRT3-mediated IDH2 activity, which regenerates NADPH for glutathione recycling within mitochondria.
• 8-OHdG — A urinary marker of oxidative DNA damage; elevated in conditions of excess mitochondrial ROS production. Measured by ELISA or LC-MS/MS.
• Acylcarnitine panel — Reflects fatty acid β-oxidation capacity; specific acylcarnitine signatures indicate chain-length-specific enzymatic impairments within the mitochondrial matrix. Available in plasma or dried blood spots via tandem MS/MS.
• B-vitamin status (B2, B3, B5) — Riboflavin (FAD/FMN for Complexes I and II), niacin/NAD⁺ precursor, and pantothenate (CoA synthesis) are direct mitochondrial cofactors whose deficiency directly impairs ETC function. Assessed as part of the Biostarks Nutrition panel.
• Ferritin and iron status — Iron is a structural component of iron-sulfur clusters in Complexes I, II, and III, and of the haem groups in cytochrome c and Complex IV. Both deficiency and excess disrupt ETC function. Assessed routinely in the Biostarks Metabolic Health panel.
• hs-CRP — Systemic inflammation is both a consequence and amplifier of mitochondrial dysfunction via NF-κB activation; provides contextual framing for GDF-15 and FGF-21 elevations.
• Mitochondrial DNA copy number — A proxy for mitochondrial mass, measured by qPCR (mtDNA:nuclear DNA ratio) in whole blood or isolated PBMCs. Declining copy number is associated with aging and metabolic disease, though considerable variability across tissue types limits interpretation.

Biomarker Mapping Summary

• Mitochondrial energy capacity → NAD⁺, lactate:pyruvate ratio, CoQ10 → HPLC / LC-MS/MS / enzymatic
• Mitochondrial stress signalling → GDF-15, FGF-21 → serum ELISA
• Metabolic pathway integrity → Urinary organic acids, acylcarnitines → GC-MS / tandem MS/MS
• Redox and antioxidant defence → GSH/GSSG, 8-OHdG → LC-MS/MS / ELISA
• Mitochondrial mass → mtDNA copy number → qPCR
• ETC cofactor sufficiency → B2, B3, B5, CoQ10, ferritin → LC-MS/MS / clinical chemistry
• Systemic inflammation context → hs-CRP, homocysteine → immunoturbidimetry / immunoassay

7. How Biostarks Can Help

Monitoring mitochondrial health starts with measurable biology. Biostarks' Longevity NAD⁺ panel directly measures whole-blood NAD⁺ — the central node connecting the AMPK–SIRT1–PGC-1α axis to mitochondrial biogenesis, quality control, and aging biology. For broader metabolic and nutritional context, the Metabolic Health and Nutrition panels cover key mitochondrial cofactors including ferritin and iron status, B-vitamins, inflammatory markers, and metabolic indicators — providing a functional picture of how well the body's energy systems are operating.

Longitudinal tracking of these biomarkers — before and after dietary changes, exercise protocols, or supplementation with compounds such as NMN, NR, or Urolithin A — is the most rigorous way to assess whether interventions are producing measurable mitochondrial benefit at the biological level rather than relying on subjective endpoints alone.

References

• Mitochondria at the crossroads of health and disease — Cell — Martínez-Reyes I & Chandel NS — (2024) — Source
• Declining NAD⁺ Induces a Pseudohypoxic State Disrupting Nuclear-Mitochondrial Communication during Aging — Cell — Gomes AP et al. — (2013) — Source
• NAD⁺ metabolism and its roles in cellular processes during ageing — Nature Reviews Molecular Cell Biology — Covarrubias AJ et al. — (2021) — Source
• PGC-1α Is a Master Regulator of Mitochondrial Lifecycle and ROS Stress Response — Antioxidants — Rius-Pérez S et al. — (2023) — Source
• Mitochondrial Fusion and Fission: The fine-tune balance for cellular homeostasis — FASEB Journal — Adebayo M et al. — (2021) — Source
• The mitophagy pathway and its implications in human diseases — Signal Transduction and Targeted Therapy — Lu Y et al. — (2023) — Source
• Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents — Nature Medicine — Ryu D et al. — (2016) — Source
• The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans — Nature Metabolism — Andreux PA et al. — (2019) — Source
• Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults — Cell Reports Medicine — Singh A et al. — (2022) — Source
• Impact of the Natural Compound Urolithin A on Health, Disease, and Aging — Trends in Molecular Medicine — D'Amico D et al. — (2021) — Source
• How mitochondria produce reactive oxygen species — Biochemical Journal — Murphy MP — (2009) — Source
• Effect of the mitophagy inducer urolithin A on age-related immune decline: a randomized, placebo-controlled trial — Nature Aging — Denk D et al. — (2025) — Source